<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027923</url>
  </required_header>
  <id_info>
    <org_study_id>09-1825 / 201101703</org_study_id>
    <nct_id>NCT01027923</nct_id>
  </id_info>
  <brief_title>IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>AML</acronym>
  <official_title>A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase I extension study, the investigators seek to test the safety of both higher&#xD;
      doses of plerixafor as well as intravenous dosing to maximize inhibition of the target,&#xD;
      CXCR4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we are seeking to target the leukemia microenvironment to overcome disease&#xD;
      resistance. We hypothesize that by disrupting the interaction of leukemic blasts with the&#xD;
      bone marrow microenvironment, we may sensitize leukemic blasts to the effects of cytotoxic&#xD;
      chemotherapy. In current formulations, the volume of plerixafor required to administer doses&#xD;
      higher than 240 mcg/kg may result in significant discomfort with repeated daily injections.&#xD;
      In this phase I extension study, we seek to test the safety of both higher doses of&#xD;
      plerixafor as well as intravenous dosing to maximize inhibition of the target, CXCR4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawal of support from sponsor&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose and dose limiting toxicities of intravenous plerixafor when combined with MEC in patients with relapsed or refractory AML.</measure>
    <time_frame>Days 1-42 (all patients have to complete)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the complete response rate (CR) for plerixafor when combined with MEC in patients with relapsed or refractory AML.</measure>
    <time_frame>Between days 15-42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of plerixafor in combination with MEC</measure>
    <time_frame>Minimum of 30 days following completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the PK and explore potential PK drug-drug interactions between plerixafor and MEC.</measure>
    <time_frame>Predose, 15 min, 30 min , and 10 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to hematologic recovery</measure>
    <time_frame>For up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the mobilization of leukemic cells with plerixafor plus G-CSF.</measure>
    <time_frame>Baseline, 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the effects of plerixafor plus G-CSF on SDF-1/CXCR4 signaling on leukemic blasts.</measure>
    <time_frame>Baseline, 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to overall survival</measure>
    <time_frame>For up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to event-free survival</measure>
    <time_frame>For up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to duration of remission</measure>
    <time_frame>For up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to relapse-free survival</measure>
    <time_frame>For up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5&#xD;
Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5&#xD;
Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5&#xD;
Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5&#xD;
Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5&#xD;
Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5&#xD;
Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5&#xD;
Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5&#xD;
Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5&#xD;
Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>AMD3100</other_name>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>Novantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>Etopophos</other_name>
    <other_name>Toposar</other_name>
    <other_name>VePesid</other_name>
    <other_name>VP156</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>Cytosar-U</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia diagnosed according to WHO criteria with one of the following:&#xD;
&#xD;
               -  Primary refractory disease following ≥ 1 round of induction chemotherapy&#xD;
&#xD;
               -  First relapse or higher&#xD;
&#xD;
          -  Age between 18 and 70 years&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x institutional ULN&#xD;
&#xD;
               -  AST ≤ 2 x ULN except when in the opinion of treating physician is due to direct&#xD;
                  involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to&#xD;
                  leukemia)&#xD;
&#xD;
               -  ALT ≤ 2 x ULN except when in the opinion of treating physician is due to direct&#xD;
                  involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to&#xD;
                  leukemia)&#xD;
&#xD;
               -  Total bilirubin ≤ 2 x ULN except when in the opinion of treating physician is due&#xD;
                  to direct involvement of leukemia (e.g., hepatic infiltration or biliary&#xD;
                  obstruction due to leukemia)&#xD;
&#xD;
               -  Left ventricular ejection fraction of ≥ 40% by MUGA scan or echocardiogram&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males must be willing and able to&#xD;
             use effective contraception while on study&#xD;
&#xD;
          -  Able to provide signed informed consent prior to registration on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants)&#xD;
&#xD;
          -  Peripheral blood blast count ≥ 50 x 103 /mm3&#xD;
&#xD;
          -  Active CNS involvement with leukemia&#xD;
&#xD;
          -  Previous treatment with MEC or other regimen containing both mitoxantrone and&#xD;
             etoposide&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Concurrently receiving any other investigational agent&#xD;
&#xD;
          -  Received colony stimulating factors filgrastim or sargramostim within 48 hours or&#xD;
             pegfilgrastim within 14 days of study&#xD;
&#xD;
          -  Less than 2 weeks from the completion of any previous cytotoxic chemotherapy&#xD;
             (excluding hydroxyurea)&#xD;
&#xD;
          -  Severe concurrent illness that would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Uy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Plerixafor</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

